Antengene (HKG:6996) narrowed its attributable loss to 76.4 million yuan in the first half of 2025 from 167 million yuan a year prior, a Friday Hong Kong bourse filing said.
The pharmaceutical company's loss per share was 0.12 yuan, narrower from 0.27 yuan in the year-ago period.
Revenue fell to 53.2 million yuan from 60.8 million yuan in the first half of 2024.